Importantly, our expanded in vivo studies using three independent colon cancer models (HCT116 and CT26 with wild-type p53; SW480 with mutant p53) conclusively show that nutlin-3a-mediated chemosensitization is not restricted by the p53 status. Here, TP53 is linked to colonic neoplasm.